FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304820> ?p ?o ?g. }

• W4367304820 abstract "<h3>Objective:</h3> We aim to determine whether a relationship exists between immunocompromise as defined by autoimmune disease or immunosuppressive and immunomodulatory medications in patients and incident HSVE. <h3>Background:</h3> Among infectious etiologies of encephalitis, herpes simplex virus type 1 (HSV-1) is commonest. The association between immune status and HSVE is unclear. Using a U.S. Medicaid database of 75.6 million persons, we evaluated the association between HSVE and autoimmune conditions, exposure to immunosuppressive and immunomodulatory medications, and other medical comorbidities. <h3>Design/Methods:</h3> We used the U.S. Medicaid Analytic eXtract Database between the years of 2007–2010 from the 29 most populated American states. We first examined the crude incidence of HSVE in the population. We then age- and sex-matched adult cases of HSVE with a sufficient enrolment period to a larger control population without HSVE. In a case-control analysis, we examined the association between HSVE and exposure to both autoimmune disease and immunosuppressive/immunomodulatory medications. Analyses were conducted with conditional logistic regression progressively adjusting for sociodemographic factors, Charlson comorbidity index, and non-autoimmune comorbidities. <h3>Results:</h3> Incidence of HSVE was ~3.01 per 10⁵ person-years among adults. A total of 951 HSVE cases and 95,100 age- and sex-matched controls were compared. The HSVE population had higher rates of medical comorbidities than the control population. The association of HSVE and autoimmune conditions was strong, adjusted OR 2.6 (95% CI [2.2, 3.2]). The association of HSVE and immunomodulating medications had an OR of 2.2 [1.9, 2.6], also after covariate adjustment. When both exposures were included in regression models, the associations remained robust: 2.3 [1.9, 2.7] for autoimmune disease and 2.0 [1.7, 2.3] for immunosuppressive and immunomodulatory medications. <h3>Conclusions:</h3> In a large, national population, HSVE is strongly associated with pre-existing autoimmune disease and exposure to immunosuppressive and immunomodulatory medications. The role of antecedent immune-related dysregulation may have been underestimated to date. <b>Disclosure:</b> Dr. Tang has received personal compensation for serving as an employee of Third Rock Ventures. Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Bhattacharyya has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Continuum. The institution of Dr. Bhattacharyya has received research support from Alexion Pharmaceuticals. The institution of Dr. Bhattacharyya has received research support from National Institute of Health. The institution of Dr. Bhattacharyya has received research support from UCB. Dr. Bhattacharyya has received publishing royalties from a publication relating to health care. Dr. Bhattacharyya has received publishing royalties from a publication relating to health care. Dr. Bhattacharyya has received publishing royalties from a publication relating to health care. Dr. Miyawaki has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Family Health, Inc.. Dr. Miyawaki has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Morrison and Mahoney. Dr. Miyawaki has stock in Cincinnati Bengals. Dr. Miyawaki has received publishing royalties from a publication relating to health care. Dr. Miyawaki has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with US Department of Health and Human Services. Dr. Yoshida has received personal compensation for serving as an employee of OM1, Inc. Dr. Yoshida has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for OM1, Inc. Dr. Wilcox has nothing to disclose. Karen Costenbader has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Karen Costenbader has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Karen Costenbader has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Glaxo Smith Kline. Karen Costenbader has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca Pharmaceuticals LP. Karen Costenbader has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Arthritis and Rheumatology. Karen Costenbader has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Uptodate. Karen Costenbader has stock in Neutrolis. The institution of Karen Costenbader has received research support from Gilead. The institution of Karen Costenbader has received research support from Exagen. The institution of Karen Costenbader has received research support from Merck. Karen Costenbader has received personal compensation in the range of $0-$499 for serving as a grant reviewer with NIH. Prof. Solomon has nothing to disclose. Mr. Guan has nothing to disclose. Miss Lahey has nothing to disclose." @default.
• W4367304820 created "2023-04-29" @default.
• W4367304820 creator A5003836713 @default.
• W4367304820 creator A5009512071 @default.
• W4367304820 creator A5019123260 @default.
• W4367304820 creator A5040379318 @default.
• W4367304820 creator A5058615857 @default.
• W4367304820 creator A5064181183 @default.
• W4367304820 creator A5067866856 @default.
• W4367304820 creator A5081412163 @default.
• W4367304820 creator A5086351530 @default.
• W4367304820 date "2023-04-25" @default.
• W4367304820 modified "2023-09-30" @default.
• W4367304820 title "Immunocompromise and herpes simplex virus type 1 encephalitis (HSVE): a nationwide cohort and case-control study (S25.009)" @default.
• W4367304820 doi "https://doi.org/10.1212/wnl.0000000000202070" @default.
• W4367304820 hasPublicationYear "2023" @default.
• W4367304820 type Work @default.
• W4367304820 citedByCount "0" @default.
• W4367304820 crossrefType "proceedings-article" @default.
• W4367304820 hasAuthorship W4367304820A5003836713 @default.
• W4367304820 hasAuthorship W4367304820A5009512071 @default.
• W4367304820 hasAuthorship W4367304820A5019123260 @default.
• W4367304820 hasAuthorship W4367304820A5040379318 @default.
• W4367304820 hasAuthorship W4367304820A5058615857 @default.
• W4367304820 hasAuthorship W4367304820A5064181183 @default.
• W4367304820 hasAuthorship W4367304820A5067866856 @default.
• W4367304820 hasAuthorship W4367304820A5081412163 @default.
• W4367304820 hasAuthorship W4367304820A5086351530 @default.
• W4367304820 hasConcept C120665830 @default.
• W4367304820 hasConcept C121332964 @default.
• W4367304820 hasConcept C126322002 @default.
• W4367304820 hasConcept C2779159551 @default.
• W4367304820 hasConcept C2908647359 @default.
• W4367304820 hasConcept C61511704 @default.
• W4367304820 hasConcept C71924100 @default.
• W4367304820 hasConcept C99454951 @default.
• W4367304820 hasConceptScore W4367304820C120665830 @default.
• W4367304820 hasConceptScore W4367304820C121332964 @default.
• W4367304820 hasConceptScore W4367304820C126322002 @default.
• W4367304820 hasConceptScore W4367304820C2779159551 @default.
• W4367304820 hasConceptScore W4367304820C2908647359 @default.
• W4367304820 hasConceptScore W4367304820C61511704 @default.
• W4367304820 hasConceptScore W4367304820C71924100 @default.
• W4367304820 hasConceptScore W4367304820C99454951 @default.
• W4367304820 hasLocation W43673048201 @default.
• W4367304820 hasOpenAccess W4367304820 @default.
• W4367304820 hasPrimaryLocation W43673048201 @default.
• W4367304820 hasRelatedWork W1580426574 @default.
• W4367304820 hasRelatedWork W1970383787 @default.
• W4367304820 hasRelatedWork W1986078235 @default.
• W4367304820 hasRelatedWork W2043123170 @default.
• W4367304820 hasRelatedWork W2089620537 @default.
• W4367304820 hasRelatedWork W2275480158 @default.
• W4367304820 hasRelatedWork W3095306390 @default.
• W4367304820 hasRelatedWork W3209251735 @default.
• W4367304820 hasRelatedWork W4238089809 @default.
• W4367304820 hasRelatedWork W4241346791 @default.
• W4367304820 isParatext "false" @default.
• W4367304820 isRetracted "false" @default.
• W4367304820 workType "article" @default.